Comparing more versus fewer needle agitations during EBUS-TBNA for mediastinal lymph node biopsy

A Randomized, Single-Blind Controlled Trial Comparing Two Needle Agitation Strategies During Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Diagnostic Yield in Patients With Enlarged Mediastinal Lymph Nodes

Not applicable Interventional University Medical Center Ho Chi Minh City (UMC) · NCT07424807

This test will see if using more or fewer needle agitations during EBUS-guided needle biopsies helps doctors obtain longer tissue cores and higher-quality samples in adults with enlarged mediastinal lymph nodes.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment180 (estimated)
Ages18 Years and up
SexAll
SponsorUniversity Medical Center Ho Chi Minh City (UMC) Academic / other
Locations1 site (Ho Chi Minh City, Ho Chi Minh)
Trial IDNCT07424807 on ClinicalTrials.gov

What this trial studies

Adults needing EBUS-TBNA for enlarged mediastinal or hilar lymph nodes (short-axis ≥10 mm) will be randomized to one of two predefined needle agitation strategies during each needle pass. Operators will standardize other procedural variables while pathologists blinded to allocation will measure outcomes including diagnostic yield, tissue core length, specimen adequacy, and procedure-related complications. The trial is single-blind and focuses on objective specimen metrics and safety events to isolate the effect of agitation number. Findings will determine whether changing the number of needle agitations improves sample quality or alters procedural risk.

Who should consider this trial

Good fit: Adults (≥18 years) with enlarged mediastinal or hilar lymph nodes (short-axis ≥10 mm) who are scheduled for clinically indicated EBUS-TBNA and can provide informed consent.

Not a fit: Patients with uncorrected bleeding disorders, recent myocardial infarction or unstable cardiac status, severe airway obstruction, hemodynamic instability, respiratory failure, intractable cough, or other contraindications to bronchoscopy are unlikely to benefit because they are excluded or unsafe to enroll.

Why it matters

Potential benefit: If successful, the preferred agitation method could increase diagnostic yield and reduce repeat biopsies by producing longer, more adequate tissue cores without raising complication rates.

How similar studies have performed: There is limited high-quality evidence defining an optimal needle agitation number, so this randomized comparison addresses a novel but plausible procedural question rather than confirming an established technique.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥ 18 years
* Presence of enlarged mediastinal or hilar lymph nodes requiring diagnostic evaluation on chest computed tomography (CT), defined as short-axis diameter ≥ 10 mm measured on axial images
* Clinical indication for EBUS-TBNA
* Ability to provide written informed consent

Exclusion Criteria:

* Uncorrected coagulation disorders (platelet count \< 100,000/mm³; International normalized ratio (INR) \> 1.5; or prothrombin time \< 50% of control)
* Acute myocardial infarction within the preceding 4 weeks or ongoing unstable angina
* Significant upper airway obstruction (benign or malignant) with ≥ 50% reduction in tracheal lumen diameter
* Hemodynamic instability (e.g., persistent hypotension, significant arrhythmia, or need for vasopressors)
* Respiratory failure refractory to oxygen therapy, defined as sustained Peripheral oxygen saturation (SpO₂) ≤ 90% despite supplemental oxygen
* Intractable cough precluding bronchoscopy
* History of severe allergy to local anesthetics or sedative agents used during the procedure
* Refusal or inability to provide informed consent

Where this trial is running

Ho Chi Minh City, Ho Chi Minh

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Mediastinal LymphadenopathyEBUS-TBNANeedle AgitationTissue Core LengthSpecimen AdequacyMediastinal Lymph NodesRandomized Controlled Trialdiagnostic yield
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.